Droplet Biosciences Targets Lymph Fluid in New Residual Cancer Detection Strategy

With an $8M seed investment led by The Engine, Droplet will develop a liquid biopsy test using lymphatic fluid rather than blood plasma as a source for detecting cancer-associated DNA alterations.

March 16, 2023

Read the full article on GenomeWeb: